Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B‐Cell lymphoma ‐results of a single center, retrospective cohort in China

Treatment for relapsed/refractory Diffuse Large B‐Cell Lymphoma (R/R DLBCL) is evolving rapidly due to the emergence of novel drugs, of which histone deacetylase inhibitors (HDACis) are an important example. This study showed efficacy in patients with R/R DLBCL after failure of conventional therapie...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yawen, Xue, Hongwei, Song, Wei, Xiao, Shuxin, Jing, Fanjing, Dong, Tieying, Wang, Lili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790240/
https://www.ncbi.nlm.nih.gov/pubmed/35165928
http://dx.doi.org/10.1002/hon.2979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790240/
https://www.ncbi.nlm.nih.gov/pubmed/35165928
http://dx.doi.org/10.1002/hon.2979

Ejemplares similares